EUVIMEDEUVIMED entdecken
Validierungsstudie

The patient health questionnaire somatization-anxiety-depression scale: Validation of the PHQ-SAD in 4 clinical trials

Angela He, Kurt Kroenke, Timothy Stump, Patrick O Monahan, Jill Connors, Yelena Chernyak, Paul Musey

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120906 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Angela He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University School of Medicine, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Patient Health Questionnaire, Somatoform Disorders, Anxiety, Psychiatric Status Rating Scales. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Patient-Centered Outcomes Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Somatization, anxiety, and depression are 3 highly comorbid conditions. Although validated scales exist for each SAD triad component, a composite measure could have complementary clinical and research utility. We examine validity of the Patient Health Questionnaire Somatic-Anxiety-Depression (PHQ-SAD) scale. METHODS: Baseline data from 4 clinical trials (2 in primary care, 1 in oncology, and 1 in the emergency department) totaling 1324 patients were analyzed. The PHQ-SAD comprises 25 items including the PHQ-8 for depression, the GAD-7 for anxiety, and 10 items from the PHQ-15 for somatic symptoms. The internal reliability, minimally important difference (MID), and factorial validity of the PHQ-SAD were examined. RESULTS: Overlap of the 3 SAD symptoms across the 4 trials was substantial: the proportion with only 1 symptom of moderate severity ranged from 21 % to 43 %, whereas the proportion with moderate severity on all 3 symptoms ranged from 24 % to 46 %. The PHQ-SAD demonstrated high internal reliability (McDonald's omega of 0.88 to 0.95) in all 4 trials. PHQ-SAD scores can range from 0 to 65 (with higher scores indicating greater symptom severity), and cutpoints of 15, 30, and 45 represent mild, moderate and severe SAD symptom burden. Preliminary estimates from two distribution-based methods suggest 4 points as the PHQ-SAD minimally important difference (MID). Bi-factor analysis indicated sufficient unidimensionality of the PHQ-SAD score. CONCLUSIONS: The PHQ-SAD is a reliable and factorially valid composite measure of somatic, anxiety and depressive symptoms which may be useful as a single measure for assessing SAD symptoms and for monitoring outcomes of transdiagnostic treatments. Trial Registration clinicaltrials.gov Identifier: NCT04811521 (PACER); NCT00926588 (SCOPE); NCT00313573 (INCPAD); NCT0175730 (CAMMPS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Health QuestionnaireSomatoform DisordersAnxietyPsychiatric Status Rating ScalesDepressionAnxiety DisordersDepressive DisorderHumansFemaleMaleMiddle AgedReproducibility of ResultsAdultPsychometricsAgedSurveys and Questionnaires

Stichwörter der Autor:innen

AnxietyDepressionPsychometricsScaleSomatic symptomsSomatization

Autor:innen und Institutionen

  • Indiana University School of Medicine, Indianapolis, IN, United States.
  • Department of Medicine, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, United States. Electronic address: kkroenke@regenstrief.org.
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, United States.
  • Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, United States.
  • Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States.
  • Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Förderung

  • Patient-Centered Outcomes Research Institute

Zitieren

APA

He, A., Kroenke, K., Stump, T., Monahan, P. O., Connors, J., Chernyak, Y., & Musey, P. (2026). The patient health questionnaire somatization-anxiety-depression scale: Validation of the PHQ-SAD in 4 clinical trials. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120906

Vancouver

He A, Kroenke K, Stump T, Monahan PO, Connors J, Chernyak Y, et al. The patient health questionnaire somatization-anxiety-depression scale: Validation of the PHQ-SAD in 4 clinical trials. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120906

BibTeX
@article{He2026,
  author = {He, Angela and Kroenke, Kurt and Stump, Timothy and Monahan, Patrick O and Connors, Jill and Chernyak, Yelena and Musey, Paul},
  title = {The patient health questionnaire somatization-anxiety-depression scale: Validation of the PHQ-SAD in 4 clinical trials},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120906}
}
Kostenlos starten →